AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05495620
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or intravenous
Trial: NCT05328804
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT05328804
Drug: Herombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally by mouth
Trial: NCT05425914
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment option for dry eye patients with low serum vitamin D Level
Trial: NCT05425914
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dry eye treatment
Trial: NCT05399641
Drug: Ibrexafungerp
RxNorm normalized name: Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each day dosing will consist of two 150mg tablets taken BID.
Trial: NCT05658549
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine dosage 600 mg and 1200 mg
Trial: NCT06091085
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
Trial: NCT05494567
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
Trial: NCT05494567
Drug: Tamsulosin Hcl 0.4 mg
RxNorm normalized name: tamsulosin HCl 0.4 mg ORAL CAPSULE
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
Trial: NCT05494567
Drug: solifenacin 10 mg
RxNorm normalized name: solifenacin 10 mg oral tablet
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
Trial: NCT05586009
Drug: cisplatin with hydration magnesium
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
Trial: NCT05577845
Drug: Ramosetron
RxNorm normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ramosetron, 4 weeks
Trial: NCT05453383
Drug: Anlotinib;Toripalimab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride;Toripalimab injiection
Trial: NCT05131984
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
Trial: NCT06009705
Drug: toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
Trial: NCT06099093
Drug: 18F-DCFPyl
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorine-labeled small molecule, via intravenous infusion per protocol.
Trial: NCT06040099
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (intravenous)
Trial: NCT06040099
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab IV (intravenous)
Trial: NCT00002132
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002132
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05345509
Drug: Aricept Tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil Tablet once daily P.O
Trial: NCT00002361
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002361
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06547489
Drug: Zelquistinel
RxNorm normalized name: Zelquistinel
DrugBank: Zelquistinel (DB19336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Trial: NCT05709288
Drug: BBM-H901
RxNorm normalized name: BBM-H901
DrugBank: BBM-H901 (DB17704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
Trial: NCT04533490
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
Trial: NCT05024799
Drug: Butorphanol and propofol
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this group will be administered with butorphanol and propofol
Trial: NCT05024799
Drug: Butorphanol and dexmedetomindine
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in this group will be administered with butorphanol and dexmedetomindine
Trial: NCT04858711
Drug: ketamine-lidocaine-dexmedetomidine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
Trial: NCT05205759
Drug: Bamlanivimab Etesevimab
RxNorm normalized name: Etesevimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
Trial: NCT05205759
Drug: Sotrovimab
RxNorm normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
Trial: NCT05205759
Drug: Casirivimab-Imdevimab
RxNorm normalized name: casirivimab-imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
Trial: NCT00000961
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04723810
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Trial: NCT00021463
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021463
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00021463
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021463
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05715528
Drug: Obeldesivir
RxNorm normalized name: Obeldesivir
DrugBank: Obeldesivir (DB18821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally without regard to food.
Trial: NCT05715528
Drug: Obeldesivir Placebo
DrugBank: Obeldesivir (DB18821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally without regard to food.
Trial: NCT06490341
Drug: GP Regimen, Nimotuzumab, Sintilimab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine,ciplatin, nimotuzumab, sintilimab
Trial: NCT06091657
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT06141031
Drug: TTI-101
RxNorm normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
Trial: NCT03953144
Drug: IC-Green (ICG)
RxNorm normalized name: acid green 50
DrugBank: Indocyanine green acid form (DB09374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Trial: NCT06369610
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given abiraterone acetate
Trial: NCT05009992
Drug: Paxalisib
RxNorm normalized name: Paxalisib
DrugBank: Paxalisib (DB15186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04914234
Drug: Atenolol Succinate Oral Tablet
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg
Trial: NCT04914234
Drug: Metoprolol Succinate Oral Tablet
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg
Trial: NCT06538181
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
Trial: NCT04931849
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
Trial: NCT06109467
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
Trial: NCT06109467
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
Trial: NCT06109467
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
Trial: NCT06109467
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
Trial: NCT05020925
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) on Day 1 of each cycle
Trial: NCT05020925
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famitinib, po, qd
Trial: NCT04734665
Drug: Niraparib-Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Trial: NCT05376566
Drug: Hydrochloric Acid (2 M)
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
Trial: NCT05205486
Drug: Cefazolin 3gm for Injection USP and Dextrose Injection USP
RxNorm normalized name: vasopressin (USP) Injection
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg
Trial: NCT05321069
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT05953038
Drug: Lysergic Acid Diethylamide Tartrate
RxNorm normalized name: diethylamine salicylate
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
Trial: NCT06419660
Drug: BI 300202
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 300202
Trial: NCT06419660
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole
Trial: NCT04710732
Drug: Standard Enoxaparin 40 mg once-daily before randomization
RxNorm normalized name: lisinopril
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2
Trial: NCT04710732
Drug: Standard Enoxaparin 40 mg once-daily after randomization
RxNorm normalized name: lisinopril
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
Trial: NCT04710732
Drug: Escalated Enoxaparin 30 mg twice-daily after randomization
RxNorm normalized name: clindamycin
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
Trial: NCT05467475
Drug: BI 1819479
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1819479
Trial: NCT05467475
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole
Trial: NCT05669768
Drug: Pamiparib/Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
Trial: NCT05005455
Drug: bevacizumab with new manufacturing process.
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg,I.V.,single dose
Trial: NCT05005455
Drug: bevacizumab with old manufacturing process.
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg,I.V.,single dose
Trial: NCT05482074
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, twice a day, dosage per protocol, per 28 day cycle
Trial: NCT04507841
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
Trial: NCT05529056
Drug: Atropine Sulfate 01
RxNorm normalized name: atropine sulfate 0.01 MG/MG
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 01 ophthalmic solution
Trial: NCT05529056
Drug: Atropine Sulfate 02
RxNorm normalized name: atropine sulfate 0.02 MG
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 02 ophthalmic solution
Trial: NCT05529056
Drug: Atropine Sulfate 03
RxNorm normalized name: atropine sulfate 0.03 MG
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 03 ophthalmic solution
Trial: NCT04098666
Drug: extended release metformin
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin extended release 500 mg tablets, up to 4 tablets a day
Trial: NCT06541067
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose
Trial: NCT05162027
Drug: Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
RxNorm normalized name: erenumab-aooe 70 MG in 1 mL Prefilled Syringe
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Trial: NCT04750759
Drug: Niclosamide + Camostat
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide will be applied in combination with camostat.
Trial: NCT06061536
Drug: DTG
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DTG +3TC + TDF（once daily）.
Trial: NCT05199662
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
Trial: NCT06573970
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
Trial: NCT06327685
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Avapritinib is an oral tyrosine kinase inhibitor.
Trial: NCT06327685
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine is a nucleoside metabolic inhibitor given intravenously.
Trial: NCT06106022
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered orally